MarketPulse

triple agonist

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Lilly's Retatrutide Hits Surgery-Level Weight Loss, But IP Wars Loom

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.
PFELLYSNYNVOintellectual propertyweight loss
BenzingaBenzinga··Vandana Singh

Novo Nordisk's Experimental Obesity Drug Shows Superior Results to Semaglutide

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.
LLYNVOweight losssemaglutide
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss